In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate
about
Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in ratsEffects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the ratNeuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-2084665-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's diseaseRole of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine.Semi-micro liquid chromatography of aromatic amino acid metabolites using isocratic elution and column switching.E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat.5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585.Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.The neurochemistry of waking and sleeping mental activity: the disinhibition-dopamine hypothesis.Alzheimer's disease and age-related memory decline (preclinical)5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms.Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment.Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain.A quantitative structure-activity relationship study on serotonin 5-HT6) receptor ligands: indolyl and piperidinyl sulphonamides.Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease.Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis.Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse.The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.Dorsomedial prefrontal cortex 5-HT6 receptors regulate anxiety-like behavior.5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice.Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).
P2860
Q24602751-205A0502-9814-4E9D-9D0F-83ADEC65B60BQ24651957-C1866EE2-072B-4B5D-9010-40577C9D12DCQ28236198-06CB4724-0625-4D34-9B10-0394DDAD27DFQ28287100-331EA144-81CC-474C-9462-A9451EEEBA00Q28395100-1CCF963D-1DB8-462C-A62E-4C1138EEF2DCQ30491992-008D42D1-7434-4E1A-B7D7-EC23AE4358C2Q31109222-8D5D6A48-DE24-49F4-BD9B-F112B7956791Q34111024-765FBB5C-EF34-489F-BA08-6C667FD59E93Q34138219-CE4C303E-16F6-4C6E-8D5D-23FD9F9DEF6AQ34177643-DC4A57AC-9125-46B2-AF9B-88C396D7047BQ34271590-06C53DA2-9585-4C8C-A924-442ED0D7E7EFQ34730873-599D746A-C2F9-4DE4-AFBF-78B3C74145DCQ35041190-5039BBB8-E2EB-4EE5-964B-FD85630457EBQ36346938-416036F8-A4A6-4425-ACC8-FD3250CA1CCBQ37954123-2F7D6193-A328-450D-AF43-E1FCC3EF0348Q38027891-F0FB16AC-4B6E-407A-A085-1258FD264D20Q38683808-039CD6E4-D3B9-49E2-BF49-8940C1E7A5C1Q39158422-6A6C91B8-0983-4465-B226-C578325AA65AQ41307502-70267F20-5217-437B-AFFA-D7081ED726E2Q43026448-1945F2F5-FCD5-45D7-AFC6-CBD3ECCCE8A4Q44626972-725301A9-DFB4-4614-A43F-757924A6C552Q45145553-25DEA90D-72C8-4D57-BBF5-E0FBA302B195Q45776602-411D9E0B-2F7E-4466-B4E9-7C67D2383035Q46505770-0AA537E7-03E7-4D13-98CE-BABEA1AF2CB0Q46547641-C0078D55-4CB4-4A15-BA80-13042B8DB4DAQ47587262-71828641-44D0-4F82-AFC8-7FD5710060D7Q50965059-3BA027AB-BFC8-4A1D-9CEA-EBF3267CD6CBQ55421497-BA4E2510-9C7C-4A59-861A-EB9ACA442F77
P2860
In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@ast
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@en
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@nl
type
label
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@ast
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@en
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@nl
prefLabel
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@ast
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@en
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@nl
P2093
P2860
P356
P1476
In vivo effects of the 5-HT(6) ...... 5-HT, glutamate and aspartate
@en
P2093
P2860
P356
10.1038/SJ.BJP.0703288
P407
P577
2000-05-01T00:00:00Z